【摘要】 目的观察含洛铂的联合化疗方案治疗晚期乳腺癌的疗效和毒性不良反应。方法 33例晚期乳腺癌患者采用含洛铂(30 mg/m2)的联合化疗方案,21 d为1周期。至少化疗2个周期后,评价疗效和毒性不良反应。结果 33例患者均可评价疗效和毒性不良反应。获CR1例,PR 11例,SD 14例,PD 7例;有效率为36.4%,疾病控制率为78.8%。中位无进展生存时间为6.5个月,中位总生存时间为14个月,1年生存率为75.8%。主要毒性不良反应为骨髓抑制和胃肠道反应,经对症处理后缓解。结论含洛铂的联合方案治疗晚期乳腺癌疗效较好,毒性不良反应轻,值得临床推广。更多还原

【Abstract】 Objective To observe the efficacy and toxicity of combination regimen containing Lobaplatin in treatment of advanced breast cancer. Methods A total of thirty-three patients with advanced breast cancer were treated with Lobaplatin(30 mg/m2) and another chemotherapeutic drug with twenty-one days as a cycle. The efficacy and side effects were evaluated after at least two cycles of chemotherapy. Results The efficacy and toxicity could be evaluated in all patients with 1 of CR, 11 of PR, 14 of SD and 7 of PD. The response rate was 36.4% and the disease control rate was 78.8%. The median progression-free survival was 6.5 months and the median overall survival was 14 months. The 1-year survival rate was 75.8%. The main side effects were myelosuppression and gastrointestinal reaction and could be well tolerated. Conclusion Combination regimen containing Lobaplatin for advanced breast cancer is effective and well tolerated.更多还原